Vita Life Sciences Limited · ASX:VLS

Vita Life Sciences — H1 2015 Earnings Presentation

18 slides from Vita Life Sciences's earnings presentation, Aug 20, 2015

  1. Slide 1: Results Presentation – Half Year ended 30 June 2015

    Vita Life Sciences Ltd ASX: VSC Results Presentation Half Year ended 30 June 2015 herbso‘gold’ vitascend> VitaLife I Enriching Lives .Since 1947 20 August 2015 \ 5

  2. Slide 2: Asia Pacific pharmaceutical and healthcare over-the-counter business

     Asia Pacific pharmaceutical and healthcare over-the- counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements  750 - 800 registered sku of vitamins and supplements sold in 8 countries in the Asia Pacific region  3 major brands 1. VitaHealth: pro

  3. Slide 3: Group results: revenue, EBIT, DPS and cashflow

    Revenue ($m) EBIT ($m) 20 4 16 12 2 8 4 0 0 HY 2014 HY 2015 HY 2014 HY 2015 DPS – Interim (cps) Gross operating cashflow to EBITDA 2 150% 1.5 100% 1 50% 0.5 0 0% HY 2014 HY 2015 HY 2014 HY 2015 2

  4. Slide 4: Established markets: Australia and Singapore growth outweighed by Malaysia

    Established markets: Australia and Singapore growth outweighed by Malaysia 1) Australia: Continued growth in core Herbs of Gold brand, ongoing establishment of Vita Science brand in the pharmacy channel 2) Singapore: Continued growth in core VitaHealth brand, first sales of Herbs of Gold brand 3) Ma

  5. Slide 5: Other Asia performance adversely impacted by:

    Other Asia performance adversely impacted by: 1) Product regulation changes in China have impacted on the number of products available for sale; and 2) Ongoing under performance in Thailand culminating in a new management team being established Revenue (A$m) 4 2 0 HY 2014 HY 2015 4

  6. Slide 6: Australia / Malaysia / Singapore / Other Asia

     Australia  Herbs of Gold remains unique formulation, premium ingredient brand  VitaScience brand roll out continues into independent pharmacies  Malaysia / Singapore  As in Australia, dedicated country CEO to be implemented  Herbs of Gold brand to be introduced in Malaysia following successfu

  7. Slide 7: Australia: Sales revenue of $7.2m, an increase of 9.6%

    Revenue ($m) 8  Sales revenue of $7.2m, an increase of 9.6% 4 against half year 2014  Revenue base of the Herbs of Gold brand sustained in a competitive environment 0 2014 2015  Initial sales of the Herbs of Gold brand under international distribution agreement EBIT ($m) 2  Continued rollout of

  8. Slide 8: Singapore: Sales revenue of $3.2m, an increase of 22.2%

    Revenue ($m) 4  Sales revenue of $3.2m, an increase of 22.2% against half year 2014 2  Underperforming sales staff replaced in first half 2014 and rejuvenation of sales team has proven successful 0 2014 2015  First sales of the Herbs of Gold brand in EBIT ($m) the Singaporean market 1  Singapore

  9. Slide 9: Malaysia: Sales revenue of $5.8m, a decrease of 1.7%

    Revenue ($m) 8  Sales revenue of $5.8m, a decrease of 1.7% 4 against half year 2014  Malaysia-wide economic slowdown, 0 impacted by April introduction of GST 2014 2015 and prevailing political climate EBIT ($m)  Actions taken to maintain market share 2 through active pricing strategy  EBIT appro

  10. Slide 10: Other Asia: Sales revenue decreased by $0.6m

    Revenue ($m) 4  Sales revenue decreased by $0.6m against half year 2014  Vietnam continued revenue growth, and MLM revenue was steady  Collectively, Other Asia performance was adversely impacted by: 2  Regulatory issues in China  Management change in Thailand  Preparations for Indonesian busin

  11. Slide 11: Interim dividend declared of 1.5 cents per share

     Interim dividend declared of 1.5 cents per share for HY15 (1.5 cent HY14)  Interim dividend will be unfranked & contains 100% Conduit Foreign Income  Dividend reinvestment plan is currently suspended  The increase in gross operating cashflow conversion to 142% of EBITDA is due to timing differe

  12. Slide 12: Trading update: revised full year guidance

    Trading update  Directors revise full year revenue guidance to circa $38m;  Directors revise full year EBIT guidance to circa $5.5m 11

  13. Slide 13: Appendix

    Appendix

  14. Slide 14: Half year ended 30 June

    Half year ended 30 June 2015 2014 Change $m $m % Revenue 18.20 17.74 3% EBITDA 2.42 3.36 (28%) EBIT 2.37 3.31 (28%) Profit before tax 2.32 3.34 (31%) Profit after tax 1.56 4.66 (67%) EPS (Diluted – cents) 2.79 8.20 (66%) Dividend (cents / share) 1.50 1.50 50% 13

  15. Slide 15: Balance Sheet as at 30 June

    Balance Sheet as at 30 June 31 December 2015 2014 $m $m Current assets 22.54 20.81 Non-current assets 8.82 9.46 Total assets 31.36 30.27 Current liabilities (6.34) (5.53) Non-current liabilities (3.02) (3.17) Total Liabilities (9.36) 8.70 Net Assets 22.00 21.57 14

  16. Slide 16: Cash Flow for the half year ended 30 June

    Cash Flow for the half year ended 2015 2014 $m $m Receipts from customers 20.10 19.21 Payments to suppliers and employees (16.67) (15.81) Gross operating cash flow 3.43 3.40 EBITDA 2.42 3.36 Gross operating cash flow / EBITDA 142% 101% Net interest (paid) / received (0.05) 0.02 Income tax paid (0.41

  17. Slide 17: Contact Details

    Contact Details Telephone: +61 3 9828 0500 Website: www.vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: Suite 650, 1 Queens Road, Melbourne, VIC 3004 16

  18. Slide 18: Disclaimer

    This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dis

Vita Life Sciences — H1 2015 Earnings Presentation on 6ix